Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
breast cancer
massively parallel sequencing
micropapillary variant of mucinous carcinoma
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
01
01
2019
revised:
21
02
2019
accepted:
04
03
2019
pubmed:
8
3
2019
medline:
3
1
2020
entrez:
8
3
2019
Statut:
ppublish
Résumé
Micropapillary variant of mucinous carcinoma of the breast (MPMC) is a rare histological form of oestrogen receptor (ER)-positive invasive carcinoma that is characterised by micropapillary clusters of tumour cells in lakes of extracellular mucin. The aims of this study were to determine the genetic alterations underpinning MPMCs, and to determine whether they overlap with those of mucinous carcinomas and/or invasive micropapillary carcinomas. DNA from five MPMCs was subjected to whole-exome sequencing. Somatic mutations, copy number alterations and mutational signatures were determined with state-of-the-art bioinformatics methods. No mutations in genes significantly mutated in breast cancer, including TP53, PIK3CA, GATA3, and MAP3K1, were detected. We identified copy number alterations that have been reported in invasive micropapillary carcinomas, such as recurrent gains in 1q, 6p, 8q, and 10q, and recurrent losses in 16q, 11q, and 13q, as well as a recurrent 8p12-8p11.2 amplification encompassing FGFR1. Like mucinous carcinomas, three of the five MPMCs analysed lacked PIK3CA mutations, 1q gains, and 16q losses, which are the hallmark genetic alterations of ER-positive breast cancers, whereas two MPMCs harboured 16q losses and/or a complex pattern of copy number alterations similar to those found in breast-invasive micropapillary carcinomas. MPMCs are heterogeneous at the genetic level; some tumours show a pattern of somatic genetic alterations similar to those of mucinous carcinomas, whereas others resemble invasive micropapillary carcinomas at the genetic level. These findings suggest that MPMCs may not constitute one histological subtype, but rather a convergent phenotype that can stem from mucinous carcinomas or invasive micropapillary carcinomas.
Identifiants
pubmed: 30843622
doi: 10.1111/his.13853
pmc: PMC6591080
mid: NIHMS1016494
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-145Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Breast Cancer Research Foundation
Organisme : Cycle for Survival
Organisme : National Institutes of Health/National Cancer Institute
ID : P30CA008748
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
J Pathol. 2008 Aug;215(4):398-410
pubmed: 18484683
Mod Pathol. 2009 Nov;22(11):1401-14
pubmed: 19633645
J Pathol. 2010 Nov;222(3):282-98
pubmed: 20815046
J Clin Pathol. 2010 Dec;63(12):1043-7
pubmed: 20962055
Cell. 2011 Apr 1;145(1):30-8
pubmed: 21458666
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Blood. 2013 Feb 7;121(6):975-83
pubmed: 23212519
Hum Pathol. 2013 Aug;44(8):1577-85
pubmed: 23517923
Nat Genet. 2014 Jan;46(1):33-8
pubmed: 24316979
J Pathol. 2014 Apr;232(5):553-65
pubmed: 24395524
J Natl Cancer Inst. 2015 Feb 23;107(5):null
pubmed: 25713166
Breast Cancer Res Treat. 2015 Jun;151(2):443-51
pubmed: 25953688
J Pathol. 2015 Oct;237(2):179-89
pubmed: 26095796
Breast Cancer Res Treat. 2016 Feb;156(1):21-32
pubmed: 26907767
Mod Pathol. 2016 Nov;29(11):1292-1305
pubmed: 27491809
Cancer Res. 2016 Dec 15;76(24):7118-7129
pubmed: 27913435
NPJ Breast Cancer. 2016 Nov 16;2:16036
pubmed: 28721389
Am J Pathol. 2017 Oct;187(10):2139-2151
pubmed: 28736315
Breast J. 2018 May;24(3):339-342
pubmed: 29063656
J Pathol. 2018 Feb;244(2):143-150
pubmed: 29149504
NPJ Breast Cancer. 2018 Mar 7;4:5
pubmed: 29532008
Histopathology. 2018 Aug;73(2):339-344
pubmed: 29603332
Nat Commun. 2018 May 8;9(1):1816
pubmed: 29739933
Nat Commun. 2018 Aug 30;9(1):3533
pubmed: 30166553
J Natl Cancer Inst. 2019 Jan 11;:null
pubmed: 30649385